Lipoprotein (a): A new target for pharmacological research and an option for treatment
European Journal of Internal Medicine · 2025-09 · 139 · 106425
DOI: 10.1016/j.ejim.2025.07.021 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Internal Medicine, 2025-09. Verfasst von Angela Pirillo und 1 weiteren Autor:innen. Beteiligte Einrichtung: Center for the Study of Atherosclerosis, E. Bassini Hospital, Cinisello Balsamo, Milan, Italy. Hauptthemen laut MEDLINE: Lipoprotein(a), Atherosclerosis, Cardiovascular Diseases. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 103 Literaturangaben.
Abstract (Originalsprache)
Lipoprotein(a) [Lp(a)] is increasingly recognised as a crucial and independent risk factor for atherosclerotic cardiovascular disease (ASCVD), calcific aortic valve stenosis (AVS), and possibly heart failure and peripheral artery disease. Lp(a) consists of an LDL-like particle covalently bound to apolipoprotein(a) [apo(a)], a highly polymorphic protein encoded by the LPA gene. The Lp(a) level in plasma is predominantly genetically determined and remains stable throughout life, relatively unaffected by lifestyle, comorbidities or standard lipid-lowering therapies. Elevated Lp(a) levels are associated with a higher risk of ASCVD, particularly in individuals with familial hypercholesterolaemia or smaller apo(a) isoforms. Despite its clinical relevance, Lp(a) is rarely measured in daily clinical practice, although most guidelines recommend at least one lifetime measurement. Novel RNA-based therapies, including antisense oligonucleotides (pelacarsen) and small interfering RNAs (olpasiran, lepodisiran, zerlasiran)-have shown the potential to reduce Lp(a) levels by >80 %. The small oral molecule muvalaplin also shows promise in inhibiting Lp(a) formation. Large-scale clinical trials are underway to assess the effects of Lp(a)-lowering therapies on cardiovascular outcomes. Measurement of Lp(a) and characterisation of the isoforms remain a challenge, and standardisation of assays is still a matter of debate. As new therapeutic options are developed that specifically target Lp(a), the inclusion of Lp(a) in cardiovascular risk assessment could improve stratification and lead to targeted interventions, particularly in high-risk populations. The growing body of genetic, epidemiological and clinical evidence makes Lp(a) a critical target in cardiovascular research and therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for the Study of Atherosclerosis, E. Bassini Hospital, Cinisello Balsamo, Milan, Italy.
- Center for the Study of Atherosclerosis, IRCCS MultiMedica, Via Milanese 300, 20099 Sesto S. Giovanni, Milan, Italy; Department of Pharmacological and Biomolecular Sciences, University of Milan, Via Balzaretti, 9 20133…
Zitieren
APA
Pirillo, A., & Catapano, A. L. (2025). Lipoprotein (a): A new target for pharmacological research and an option for treatment. European Journal of Internal Medicine, 139, 106425. https://doi.org/10.1016/j.ejim.2025.07.021
Vancouver
Pirillo A, Catapano AL. Lipoprotein (a): A new target for pharmacological research and an option for treatment. European Journal of Internal Medicine. 2025;139:106425. doi:10.1016/j.ejim.2025.07.021
BibTeX
@article{Pirillo2025,
author = {Pirillo, Angela and Catapano, Alberico L},
title = {Lipoprotein (a): A new target for pharmacological research and an option for treatment},
journal = {European Journal of Internal Medicine},
year = {2025},
volume = {139},
pages = {106425},
doi = {10.1016/j.ejim.2025.07.021}
}
EUVIMED